Melissa Tjota to Biomarkers, Tumor
This is a "connection" page, showing publications Melissa Tjota has written about Biomarkers, Tumor.
Connection Strength
1.236
-
TSC/MTOR-mutated eosinophilic renal tumors are a distinct entity that is CK7+/CK20-/vimentin-: a validation study. Hum Pathol. 2021 09; 115:84-95.
Score: 0.434
-
Eosinophilic Renal Cell Tumors With a TSC and MTOR Gene Mutations Are Morphologically and Immunohistochemically Heterogenous: Clinicopathologic and Molecular Study. Am J Surg Pathol. 2020 07; 44(7):943-954.
Score: 0.420
-
Clinical Utility and Benefits of Comprehensive Genomic Profiling in Cancer. J Appl Lab Med. 2024 Jan 03; 9(1):76-91.
Score: 0.134
-
TSC/MTOR mutated renal cell carcinoma with leiomyomatous stroma is a distinct entity: a comprehensive study of 12 cases. Hum Pathol. 2023 04; 134:124-133.
Score: 0.125
-
Mesothelioma in situ of the peritoneum: report of three cases and review of the literature. Histopathology. 2024 Feb; 84(3):492-506.
Score: 0.033
-
Characterizing the distribution of alterations in mesothelioma and their correlation to morphology. Am J Clin Pathol. 2023 09 01; 160(3):238-246.
Score: 0.033
-
NF2-mutated Renal Carcinomas Have Common Morphologic Features Which Overlap With Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma: A Comprehensive Study of 14 Cases. Am J Surg Pathol. 2022 05 01; 46(5):617-627.
Score: 0.030
-
EZR-ROS1 fusion renal cell carcinoma mimicking urothelial carcinoma: report of a previously undescribed gene fusion in renal cell carcinoma. Virchows Arch. 2022 Feb; 480(2):487-492.
Score: 0.028